Skip to search formSkip to main contentSkip to account menu

eprosartan mesylate dihydrate

Known as: epro-sartan mesylate dihydrate 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

ImidazolesThiophenes

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Erkrankungsstatus und Technikskills Willingness of Patients with Breast Cancer in the Adjuvant andMetastatic Setting to Use Electronic Surveys ( ePRO ) Depends on Sociodemographic Factors , Health…
  • 2016
  • Corpus ID: 131766174
Einleitung: Aufgrund der häufig ungünstigen Prognose insbesondere in der metastasierten Situation ist die gesundheitsbezogene… 
Review
2014
Review
2014
Supportive care plans: Harnessing technology and patient-reported outcomes to drive quality care across the cancer continuum.
167 Background: Cancer care is increasingly complex. Clinicians lack time to stay current on evolving evidence and resources to… 
2012
2012
Projekt iLab EPRO
2008
2008
r epro Ductive health o F the Flori Da Flock o F intro Duce D w hooping cranes
We examined the reproductive parameters of the introduced non-migratory flock of whooping cranes in Florida. Of 289 cranes… 
2007
2007
Ååòòññð Úú Blockin Blockin¹áòòòôòòòòø Ìüø Áòôùø Ååøøó
2000
2000
State Traversal guided by Hamming Distan ePro les
1999
1999
Dehydration behavior of eprosartan mesylate dihydrate.
Eprosartan mesylate (SKF 108566-J; EM) is an antihypertensive agent approved for marketing in the USA. EM dihydrate was prepared… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)